Alirocumab substantially reduces cholesterol in adult patients with HoFH
The cholesterol drug alirocumab reduced low-density lipoprotein (LDL) cholesterol by 35.6% compared to placebo in adult patients with homozygous familial hypercholesterolemia (HoFH), according to a phase three clinical trial ...
Mar 30, 2020
0
0